<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gordon, Debra</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ezekowitz, Michael D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Newer Anticoagulants in the Treatment of Atrial Fibrillation</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">28-29</style></pages><abstract><style  face="normal" font="default" size="100%">Stroke prevention in atrial fibrillation is an evolving story and it is often predicted that the he new oral anticoagulants that are now reaching the market offer numerous advantages over vitamin K antagonists, including oral administration, therapeutic stability that does not require monitoring, once- or twice-daily administration, and a short half-life.</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>